Join our daily newsletter At The Bell to receive exclusive market insights
Paradigm Biopharmaceuticals (ASX:PAR) has kicked off the screening process for participants with osteoarthritis ahead of the company’s Hong Kong-based Phase III trial using injectable pentosan polysulfate sodium (iPPS) – which, fun fact Friday, is derived from beech trees.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with Paradigm Biopharma Ltd and is intended for informational purposes only.
On Friday, PAR reported it’s added an additional trial site to its portfolio of clinical bricks and mortar in Hong Kong; with the global PARA_OA_012 third stage clinical to set up digs in the Hong Kong Centre for Clinical Research.
Described as a “private clinical drug research” centre on its website, PAR outlined it’s on the relative cusp of hitting 50% of patient recruitment. That milestone triggers the ability to deliver an interim analysis later this year, long story short.
The global program takes place in Hong Kong but also includes a site in Moldova, Europe. When it comes to treating osteoarthritis with the investigational clinical stage iPPS candidate, the company is focusing specifically on the condition where it affects knees in trial participants.
Some 466 participants will be enrolled and the structure of the trial will be randomised placebo. Patients will be dosed for 112 days and the change in the weekly average of daily pain is the key measurement of interest for the company’s endpoints.
Paradigm Bio MD Paul Rennie highlighted the valuable relationship it has with key trial partners on Friday. “NBCD, which is supporting the Hong Kong and Moldova regions, is working alongside Advanced Clinical, which continues to manage sites across Australia and the United States,” Rennie said.
He added: “These complementary CRO partnerships strengthen our global recruitment network as we work toward completing enrolment in this Phase 3 study.”
PAR last traded at 26cps.
Join the discussion: See what HotCopper users are saying about Paradigm Biopharma Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
